SCM
ODT

Silverarc Capital Management’s Odonate Therapeutics, Inc. Common Stock ODT Stock Holding History

Silverarc Capital Management’s Portfolio ODT Stock Details ODT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-186,680
Closed -$652K – 115
2021
Q2 		$652K Sell
186,680
-313,320
-63% -$1.08M 0.29% 74
2021
Q1 		$1.71M Buy
+500,000
New +$9.45M 0.93% 40

Other funds holding ODT

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Silverarc Capital Management's ODT Position: Q3 2021 in Review

Silverarc Capital Management sold out of Odonate Therapeutics, Inc. Common Stock (ODT) in Q3 2021, closing a stake of 186,680 shares — an estimated $652K sold.

Silverarc Capital Management first reported a position in ODT in Q1 2021 and held it in 2 quarters. The position peaked at $1.71M in Q1 2021. 58 funds tracked by Wall St. Rank hold ODT as of Q3 2021.

  • Silverarc Capital Management reported no remaining Odonate Therapeutics, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Silverarc Capital Management sold 186,680 Odonate Therapeutics, Inc. Common Stock shares in Q3 2021, an estimated $652K.
  • Silverarc Capital Management first reported a position in Odonate Therapeutics, Inc. Common Stock in Q1 2021 and held it in 2 quarters.
  • Silverarc Capital Management's Odonate Therapeutics, Inc. Common Stock position peaked at $1.71M in Q1 2021.
  • 58 funds tracked by Wall St. Rank held Odonate Therapeutics, Inc. Common Stock as of Q3 2021.

Based on Silverarc Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.